

WEST

Generate Collection

Print

L2: Entry 28 of 50

File: USPT

Apr 23, 2002

US-PAT-NO: 6375957

DOCUMENT-IDENTIFIER: US 6375957 B1

TITLE: Opioid agonist/opioid antagonist/acetaminophen combinations

DATE-ISSUED: April 23, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Kaiko; Robert F.	Weston	CT		
Colucci; Robert D.	Newtown	CT		

US-CL-CURRENT: 424/400; 424/451, 424/464, 514/812

CLAIMS:

What is claimed is:

1. An oral dosage form, comprising

an orally therapeutically effective amount of

(A) ~~an opioid agonist~~;

(B) acetaminophen; and

(C) an opioid antagonist;

the dosage form having a ratio of opioid antagonist to opioid agonist to acetaminophen that provides a combination product which is analgesically effective when the combination is administered orally, but which (i) is aversive in physically dependent human subjects when administered in the same amount or in a higher amount than said therapeutically effective amount; and (ii) maintains an analgesic effect but does not increase analgesic efficacy of the opioid agonist together with the acetaminophen relative to the same therapeutic amount of opioid analgesic together with the acetaminophen when administered to human patients without said opioid antagonist.

2. The oral dosage form of claim 1, wherein the antagonist included in the oral dosage form causes an aversive experience in a physically dependent addict taking about 2-3 times said therapeutically effective amount.

3. The oral dosage form of claim 1, wherein the opioid agonist is hydrocodone and the antagonist is naltrexone.

4. The oral dosage form of claim 3, wherein the ratio of naltrexone to hydrocodone is from about 0.03:1 to about 0.27:1.

5. The oral dosage form of claim 3, wherein the ratio of naltrexone to hydrocodone is from about 0.05:1 to about 0.20:1.

6. The oral dosage form of claim 1, wherein the opioid agonist is selected from the group consisting of morphine, hydromorphone, hydrocodone, oxycodone, codeine, levorphanol, meperidine, methadone, oxymorphone, dihydrocodeine, tramadol, pharmaceutically acceptable salts thereof, and mixtures thereof.

7. The oral dosage form of claim 1, further comprising an additional non-opioid drug selected from the group consisting of an NSAID, an NMDA receptor antagonist, a drug that blocks a major intracellular consequence of NMDA-receptor activation, dimenhydrinate or a pharmaceutically acceptable salt thereof, an antitussive, an expectorant, a decongestant, an antihistamine and mixtures thereof.

8. The oral dosage form of claim 1, further comprising one or more pharmaceutically acceptable inert excipients.

9. The oral dosage form of claim 6, wherein said opioid antagonist is selected from the group consisting of naltrexone, naloxone, nalmephe, cyclazocine, levallorphan, and mixtures thereof.

10. The oral dosage form of claim 6, wherein said opioid antagonist is naltrexone.

11. The oral dosage form of claim 1, further comprising a sustained release carrier that causes said opioid agonist to be released over a time period of about 8 to about 24 hours when orally administered to a human patient.

12. The oral dosage form of claim 1, wherein said opioid antagonist is naltrexone and said opioid agonist is oxycodone, wherein the ratio of naltrexone to oxycodone is from about 0.037:1 to about 0.296:1.

13. The oral dosage form of claim 1, wherein said opioid antagonist is naltrexone and said opioid agonist is codeine, wherein the ratio of naltrexone to codeine is from about 0.005:1 to about 0.044:1.

14. The oral dosage form of claim 1, wherein said opioid antagonist is naltrexone and said opioid agonist is hydromorphone, wherein the ratio of naltrexone to hydromorphone is from about 0.148:1 to about 1.185:1.

15. The oral dosage form of claim 1, wherein said opioid antagonist is naltrexone and said opioid agonist is levorphanol, wherein the ratio of naltrexone to levorphanol is from about 0.278:1 to about 2.222:1.

16. The oral dosage form of claim 1, wherein said opioid antagonist is naltrexone and said opioid agonist is meperidine, wherein the ratio of naltrexone to meperidine is from about 0.0037:1 to about 0.0296:1.

17. The oral dosage form of claim 1, wherein said opioid antagonist is naltrexone and said opioid agonist is methadone, wherein the ratio of naltrexone to methadone is from about 0.056: 1 to about 0.444:1.

18. The oral dosage form of claim 1, wherein said opioid antagonist is naltrexone and said opioid agonist is morphine, wherein the ratio of naltrexone to morphine is from about 0.018:1 to about 0.148:1.

19. The oral dosage form of claim 11, wherein the sustained release carrier further causes said opioid antagonist to be released over a time period of about 8 to about 24 hours when orally administered to a human patient.

20. The oral dosage form of claim 19, wherein the sustained release carrier further causes the acetaminophen to be released over a time period of about 8 to about 24 hours when orally administered to a human patient.

21. The oral dosage form of claim 1, wherein the opioid agonist would be subtherapeutic if administered without the acetaminophen.
22. The oral dosage form of claim 1, wherein the acetaminophen would be subtherapeutic if administered without the opioid agonist.
23. The oral dosage form of claim 1, wherein the dosage form comprises from about 10 mg to about 2000 mg of acetaminophen.
24. The oral dosage form of claim 1, wherein the dosage form comprises from about 25 mg to about 1000 mg of acetaminophen.
25. The oral dosage form of claim 1, wherein the dosage form comprises from about 325 mg to about 1000 mg of acetaminophen.
26. The oral dosage form of claim 1, wherein the opioid agonist and the acetaminophen would each be subtherapeutic if not used in combination with each other.
27. The oral dosage form of claim 1, further comprising a sustained release carrier which causes the drugs to be released from the dosage form over a time period from about 8 hours to about 24 hours when the dosage form is orally administered to a human patient.
28. The oral dosage form of claim 27, wherein the opioid agonist is selected from the group consisting of morphine, hydromorphone, hydrocodone, oxycodone, codeine, levorphanol, meperidine, methadone, oxymorphone, dihydrocodeine, tramadol, pharmaceutically acceptable salts thereof, and mixtures thereof.
29. The oral dosage form of claim 28, wherein said opioid antagonist is selected from the group consisting of naltrexone, naloxone, nalmephen, cyclazocine, levallorphan, and mixtures thereof.
30. The oral dosage form of claim 29, wherein the dosage form comprises from about 10 mg to about 2000 mg of acetaminophen.
31. The oral dosage form of claim 27, wherein either or both the opioid agonist and the acetaminophen would be subtherapeutic if not used in combination with each other.
32. A method of treating pain, comprising:
- administering an oral dosage form which contains a therapeutically effective amount of
- (A) an opioid agonist;
- (B) acetaminophen; and
- (C) an opioid antagonist;
- the dosage form having a ratio of opioid antagonist to opioid agonist to acetaminophen that provides a combination product which is analgesically effective when the combination is administered orally, but (i) is aversive in physically dependent human subjects when administered in the same amount or a higher amount than said therapeutically effective amount; and (ii) maintains an analgesic effect but does not increase analgesic efficacy of the opioid analgesic together with the acetaminophen relative to the same therapeutic amount of opioid analgesic together with the acetaminophen when administered to human patients without said opioid antagonist.
33. The method of claim 32, wherein the antagonist included in the oral dosage

form causes an aversive experience in physically dependent addicts taking about 2-3 times said therapeutically effective amount.

34. The method of claim 32, wherein the opioid agonist is selected from the group consisting of morphine, hydromorphone, hydrocodone, oxycodone, codeine, levorphanol, meperidine, methadone, oxymorphone, dihydrocodeine, tramadol, pharmaceutically acceptable salts thereof, and mixtures thereof and the opioid antagonist is selected from the group consisting of naltrexone, naloxone, nalmeperone, cyclazocine, levallorphan, and mixtures thereof.

35. The method of claim 34, further comprising preparing said oral dosage form with a sustained release carrier such that the dosage form is administrable on a twice-a-day or on a once-a-day basis.

36. The method of claim 32, wherein the dosage form comprises from about 10 mg to about 2000 mg of acetaminophen.

37. The oral dosage form of claim 1, wherein said opioid antagonist is naltrexone and said opioid agonist is oxycodone, wherein the ratio of naltrexone to oxycodone is from about 0.056:1 to about 0.222:1.

38. The oral dosage form of claim 1, wherein said opioid antagonist is naltrexone and said opioid agonist is codeine, wherein the ratio of naltrexone to codeine is from about 0.0083:1 to about 0.033:1.

39. The oral dosage form of claim 1, wherein said opioid antagonist is naltrexone and said opioid agonist is hydromorphone, wherein the ratio of naltrexone to hydromorphone is from about 0.222:1 to about 0.889:1.

40. The oral dosage form of claim 1, wherein said opioid antagonist is naltrexone and said opioid agonist is levorphanol, wherein the ratio of naltrexone to levorphanol is from about 0.417:1 to about 1.667:1.

41. The oral dosage form of claim 1, wherein said opioid antagonist is naltrexone and said opioid agonist is meperidine, wherein the ratio of naltrexone to meperidine is from about 0.0056:1 to about 0.022:1.

42. The oral dosage form of claim 1, wherein said opioid antagonist is naltrexone and said opioid agonist is methadone, wherein the ratio of naltrexone to methadone is from about 0.083:1 to about 0.333:1.

43. The oral dosage form of claim 1, wherein said opioid antagonist is naltrexone and said opioid agonist is morphine, wherein the ratio of naltrexone to morphine is from about 0.028: 1 to about 0.111:1.

44. The oral dosage form of claim 1, further comprising an additional non-opioid drug selected from the group consisting of a COX-2 inhibitor and aspirin.

45. The method of claim 26, wherein said opioid antagonist is naltrexone and said opioid agonist is oxycodone, wherein the ratio of naltrexone to oxycodone is from about 0.056:1 to about 0.222:1.

46. The method of claim 26, wherein said opioid antagonist is naltrexone and said opioid agonist is codeine, wherein the ratio of naltrexone to codeine is from about 0.0083:1 to about 0.033:1.

47. The method of claim 26, wherein said opioid antagonist is naltrexone and said opioid agonist is hydromorphone, wherein the ratio of naltrexone to hydromorphone is from about 0.222:1 to about 0.889:1.

48. The method of claim 26, wherein said opioid antagonist is naltrexone and

said opioid agonist is levorphanol, wherein the ratio of naltrexone to levorphanol is from about 0.417:1 to about 1.667:1.

49. The method of claim 26, wherein said opioid antagonist is naltrexone and said opioid agonist is meperidine, wherein the ratio of naltrexone to meperidine is from about 0.0056:1 to about 0.022:1.

50. The method of claim 26, wherein said opioid antagonist is naltrexone and said opioid agonist is methadone, wherein the ratio of naltrexone to methadone is from about 0.083:1 to about 0.333:1.

51. The method of claim 26, wherein said opioid antagonist is naltrexone and said opioid agonist is morphine, wherein the ratio of naltrexone to morphine is from about 0.028:1 to about 0.111:1.

52. The oral dosage form of claim 1, wherein said combination decreases analgesia as assessed by direct measurement in patients or by use of one or more surrogate measures of opioid effect in human subjects.

53. The method of claim 26, wherein said ratio of opioid antagonist to opioid agonist decreases analgesia as assessed by direct measurement in patients or by use of one or more surrogate measures of opioid effect in human subjects.

54. A method of preventing oral abuse of an oral opioid formulation, comprising:

preparing an oral dosage form which comprises a therapeutically effective amount of

- (A) an opioid agonist;
- (B) acetaminophen; and
- (C) an opioid antagonist;

the dosage form having a ratio of opioid antagonist to opioid agonist to acetaminophen that provides a combination product which is analgesically effective when the combination is administered orally, but (i) is aversive in physically dependent human subjects when administered in the same amount or a higher amount than said therapeutically effective amount; and (ii) maintains an analgesic effect but does not increase analgesic efficacy of the opioid analgesic together with the acetaminophen relative to the same therapeutic amount of opioid analgesic together with the acetaminophen when administered to human patients without said opioid antagonist.

55. An oral dosage form, comprising:

an orally therapeutically effective amount of

- (A) an opioid agonist;
- (B) acetaminophen; and
- (C) an opioid antagonist;

the dosage form having a ratio of opioid antagonist to opioid agonist to acetaminophen that provides a combination product which is analgesically effective when the combination is administered orally, but which (i) is aversive in physically dependent human subjects when administered in the same amount or a higher amount than said therapeutically effective amount; and (ii) maintains or decreases analgesic efficacy of the opioid agonist together with the acetaminophen relative to the same therapeutic amount of opioid analgesic

together with the acetaminophen when administered to human patients without said opioid antagonist.

WEST

Generate Collection

Print

L2: Entry 30 of 50

File: USPT

Sep 25, 2001

DOCUMENT-IDENTIFIER: US 6294195 B1

TITLE: Orally administrable opioid formulations having extended duration of effect

Detailed Description Text (2):

The multiparticulate systems of the present invention may incorporate one or more compounds known as opioid analgesics. Opioid analgesic compounds which may be used in the present invention include alfentanil, allylprodine, alphaprodine, anileridine, benzylmorphine, bezitramide, buprenorphine, butorphanol, clonitazene, codeine, cyclazocine, desomorphine, dextromoramide, dezocine, diampromide, dihydrocodeine, dihydromorphine, dimenoxadol, dimepheptanol, dimethylthiambutene, dioxaphetyl butyrate, dipipanone, eptazocine, ethoheptazine, ethylmethylthiambutene, ethylmorphine, etonitazene fentanyl, heroin, hydrocodone, hydromorphone, hydroxypethidine, isomethadone, ketobemidone, levallorphan, levorphanol, levophenacetylmorphan, lofentanil, meperidine, meptazinol, metazocine, methadone, metopon, morphine, myrophine, nalbuphine, narceine, nicomorphine, norlevorphanol, normethadone, nalorphine, normorphine, norpipanone, opium, oxycodone, oxymorphone, papaveretum, pentazocine, phenadoxone, phenomorphan, phenazocine, phenoperidine, piminodine, piritramide, propheptazine, promedol, properidine, propiram, propoxyphene, sufentanil, tramadol, tilidine, salts thereof, mixtures of any of the foregoing, mixed mu-agonists/antagonists, mu-antagonist combinations, and the like.

Detailed Description Text (4):

In one preferred embodiment the sustained-release opioid oral dosage form of the present invention includes hydromorphone as the therapeutically active ingredient in an amount from about 4 to about 64 mg hydromorphone hydrochloride. Alternatively, the dosage form may contain molar equivalent amounts of other hydromorphone salts or of the hydromorphone base. In other preferred embodiments where the opioid analgesic is other than hydromorphone, the dosage form contains an appropriate amount to provide a substantially equivalent therapeutic effect. For example, when the opioid analgesic comprises morphine, the sustained-release oral dosage forms of the present invention include form about 5 mg to about 800 mg morphine, by weight. When the opioid analgesic comprises oxycodone, the sustained-release oral dosage forms of the present invention include from about 5 mg to about 400 mg oxycodone.

Detailed Description Text (7):

The substrates of the present invention may further include one or more additional drugs which may or may not act synergistically with the opioid analgesics of the present invention. Examples of such additional drugs include non-steroidal anti-inflammatory agents, including ibuprofen, diclofenac, naproxen, benoxaprofen, flurbiprofen, fenoprofen, flubufen, ketoprofen, indoprofen, piroprofen, carprofen, oxaprozin, pramoprofen, muprofen, trioxaprofen, suprofen, aminoprofen, tiaprofenic acid, fluprofen, bucloxic acid, indomethacin, sulindac, tolmetin, zomepirac, tiopinac, zidometacin, acemetacin, fentiazac, clidanac, oxpinac, mefenamic acid, meclofenamic acid, flufenamic acid, niflumic acid, tolfenamic acid, diflurisal, flufenisal, piroxicam, sudoxicam or isoxicam, and the like. Other suitable additional drugs which may be included in the dosage forms of the present invention include acetaminophen, aspirin, and other non-opioid analgesics.

Detailed Description Text (16):

In one preferred embodiment, the acrylic coating is an acrylic resin lacquers used in the form of an aqueous dispersion, such as that which is commercially available from Rohm Pharma under the Tradename Eudragit.RTM.. In further preferred embodiments, the acrylic coating comprises a mixture of two acrylic resin lacquers commercially available from Rohm Pharma under the Tradenames Eudragit.RTM. RL 30 D and Eudragit.RTM. RS 30 D, respectively. Eudragit.RTM. RL 30 D and Eudragit.RTM. RS 30 D are copolymers

of acrylic and methacrylic esters with a low content of quaternary ammonium groups, the molar ratio of ammonium groups to the remaining neutral (meth)acrylic esters being 1:20 in Eudragit.RTM. RL 30 D and 1:40 in Eudragit.RTM. RS 30 D. The mean molecular weight is about 150,000. The code designations RL (high permeability) and RS (low permeability) refer to the permeability properties of these agents. Eudragit.RTM. RL/RS mixtures are insoluble in water and in digestive fluids. However, coatings formed from the same are swellable and permeable in aqueous solutions and digestive fluids.

Other Reference Publication (17):

Abraham Sunshine, et al., "Analgesic oral efficacy of tramadol hydrochloride in postoperative pain", Clin. Pharmacol. Ther., Jun. 1992, pp. 740-746.

CLAIMS:

5. The dosage form of claim 1, wherein said opioid analgesic is selected from the group consisting of morphine, codeine, hydromorphone, hydrocodone, oxycodone, oxymorphone, dihydrocodeine, dihydromorphone, tramadol, and mixtures thereof.

6. The dosage form of claim 1, wherein said opioid analgesic is selected from the group consisting of alfentanil, allylprodine, alphaprodine, anileridine, benzylmorphine, bezitramide, buprenorphine, butorphanol, clonitazene, codeine, cyclazocine, desomorphine, dextromoramide, dezocine, diampromide, dihydrocodeine, dihydromorphone, dimenoxadol, dimepheptanol, dimethylthiambutene, dioxaphetyl butyrate, dipipanone, eptazocine, ethoheptazine, ethylmethylthiambutene, ethylmorphine, etonitazene fentanyl, heroin, hydrocodone, hydromorphone, hydroxypethidine, isomethadone, ketobemidone, levallorphan, levorphanol, levophenacyl morphan, lofentanil, meperidine, meptazinol, metazocine, methadone, metopon, morphine, myrophine, nalbuphine, narceine, nicomorphine, norlevorphanol, normethadone, nalorphine, normorphine, norpipanone, opium, oxycodone, oxymorphone, papaveretum, pentazocine, phenadoxone, phenomorphan, phenazocine, phenoperidine, piminodine, piritramide, propheptazine, promedol, properidine, propiram, propoxyphene, sufentanil, tramadol, tilidine, salts thereof and mixtures thereof.

16. A bioavailable sustained-release oral analgesic dosage form for once-a-day administration, comprising:

a unit dose comprising a plurality of pharmaceutically acceptable matrices comprising an analgesically effective amount of tramadol or a salt thereof, ethylcellulose and stearyl alcohol, each of said matrices having a diameter from about 0.1 mm to about 3 mm, said dosage form being bioavailable and providing a therapeutic effect for about 24 hours or more after oral administration to a human patient.

21. The dosage form of claim 1, wherein said opioid analgesic consists of tramadol or a salt thereof.

WEST

Generate Collection

Print

L2: Entry 37 of 50

File: USPT

Jun 12, 2001

DOCUMENT-IDENTIFIER: US 6245357 B1
TITLE: Extended release dosage form

Detailed Description Text (10):

In drawing FIG. 2, internal compartment 15 comprises a single homogenous composition. The compartment 15 comprises therapeutic agent 14, represented by dots. The term therapeutic agent as used herein included medicines or drugs, nutrients, vitamins, food supplements, and other beneficial agents that provide a therapeutic or a benefit to animals, including a warm-blooded animal, humans, farm animals, and zoo animals. Representative of drugs 14 comprises an opioid analgesic selected from the group consisting of alfentanil, allylprodine, alphaprodine, anileridine, benzylmorphine, bezitramide, buprenorphine, butorphanol, clonitazene, codeine, cyclazocine, desomorphine, dextromoramide, dezocine, diampromide, dihydrocodeine, dihydromorphine, dimenoxadol, diepheptanol, dimethylthiambutene, dioxaphetyl butyrate, dipipanone, eptazone, ethoheptazine, ethylmethylthiambutene, ethylmorphine, propylmorphine, etonitazene, fentanyl, heroin, hydrocodone, hydromorphone, hydroenitabas, hydrocypethidine, isomethadone, ketobemidone, levallorphan, levorphanol, levophenacymorphan, lofentanil, meperidine, meptazinol, metazocine, methadone, metopon, morphine, myrophine, nalbuphine, narceine, nicomorphine, norlevorphanol, normethadone, nalorphine, normorphine, norpipanone, opium, oxycodone, oxymorphone, papaveretum, pentazocine, phenadoxone, phenomorphine, phenazocine, phenoperidine, piminodine, piritramide, propheptazine, promedol, properidine, propiram, propoxyphene, sufentanil, tramadol, and tilidine. The dose of opioid drug 14 is 0.1 .mu.g to 700 mg.

Detailed Description Text (11):

The opioid analgesic 14 can be present in compartment 15 alone, or the opioid analgesic 14 can be present with a nonopioid analgesic 14. Examples of nonopioid analgesic comprise a member selected from the group consisting of acetaminophen, aminobenzoate potassium, aminobenzoate sodium, aspirin, benoxaprofen, benzydamine, bicifadine, decibuprofen, fenoprofen, flurbiprofen, ibufenac, indoprofen, ibuprofen, ketoprofen, naproxen, naproxol, salicylamide, sodium salicylate, and salicylate potassium. The dose of nonopioid analgesic 14 is 0.5 mg to 600 mg. An analgesic composition in compartment 15 comprises 1.0 mg to 750 mg of both the opioid analgesic and nonopioid analgesic.

Detailed Description Text (38):

where $C_{\text{sub } x}$ represents the molar concentration of any ion x in the solution and $Z_{\text{sub } x}$ represents the corresponding valence of ion x. Reference solutions of a simple salt such as sodium chloride can be prepared as the ionic strength reference. Since the value of each ionic charge Z is unity for sodium chloride, a value of one for the sodium ion and a value of one for the chloride ion, the ionic strength according to Equation 4 is directly proportional to molar concentration. A saturated solution of sodium chloride consists of 5.5 moles per liter and therefore has an ionic strength of 5.5 moles per liter. Such a saturated solution can be serially diluted with distilled water to produce a series of ionic strength reference solutions of any value less than 5.5 moles per liter for use in the reference cell to determine the effect of ionic strength on bilayer permeability as a function of ionic strength.

Detailed Description Text (57):

The hydromorphone-acetaminophen analgesic tablets are coated with an interior wall then coated by an exterior wall as follows: first, 154 g of ethyl cellulose having a molecular weight of 220,000 grams per mole and an ethoxyl content of 48.0 to 49.5 weight percent, and 112 g of hydroxypropylcellulose having a 80,000 molecular weight and a molar substitution of 3, and then 14 g of polyoxyethylene (40) stearate were dissolved with stirring in 3,720 g of anhydrous ethanol. The solution resulting was allowed to stand without stirring for 3 days, to provide the interior wall-forming

composition. Next, the exterior wall forming composition was prepared by dissolving 162.5 g of cellulose acetate having an acetyl content of 39.8 wt % and a molecular weight of 40,000 grams per mole, and 87.5 g of ethylene oxide-propylene oxide-ethylene oxide triblock copolymer having a molecular weight of approximately 8,400 grams per mole and an ethylene oxide content of 82 wt % in 4,750 g of anhydrous acetone with stirring and slight warming to 26.degree. C. The resulting exterior forming wall composition was allowed to stand at ambient room temperature for one day.

Detailed Description Text (60):

Therapeutic compositions are manufactured by following the procedure of Example 2, to provide analgesic compositions comprising 1 mg to 1000 mg of an opioid selected from the group consisting of hydromorphone, hydromorphone base, hydromorphone salt, and hydromorphone derivatives; at least one nonopioid analgesic of 1 to 1000 mg selected from the group consisting of acetaminophen, aspirin, flurbiprofen, ibuprofen, indoprofen, benoxaprofen, propoxyphene, salicylamide, zenazocine and zomepirac; with the dose of opioid and nonopioid analgesic in the composition comprising 2 mg to 1000 mg; at least one polymeric carrier for both the opioid and nonopioid analgesics selected from 10 mg to 500 mg of a poly(alkylene oxide) comprising a 100,000 to 500,000 molecular weight represented by poly(methylene oxide), poly(ethylene oxide), poly(propylene oxide), poly(isopropylene oxide) and poly(butylene oxide); or a polymeric carrier of 10 mg to 500 mg of a carboxymethylene having a 7,500 to 325,000 molecular weight represented by a member selected from the group consisting of an alkali carboxymethylcellulose, and potassium carboxymethylcellulose, calcium carboxymethylcellulose, and potassium carboxymethylcellulose; 0.5 mg to 50 mg of a poly(vinyl) polymer possessing a 5,000 to 300,000 molecular weight as represented by poly(vinyl pyrrolidone), copolymer of poly(vinyl pyrrolidone and vinyl acetate), copolymer of poly(vinyl pyrrolidone and vinyl chloride), copolymer of vinyl pyrrolidone and vinyl fluoride), copolymer of poly(vinyl pyrrolidone and vinyl butyrate), copolymer of poly(vinyl pyrrolidone and vinyl laurate) and copolymer of poly(vinyl pyrrolidone and vinyl stearate); and 0 to 7.5 mg of a lubricant represented by a member selected from the group consisting of polyethylene glycol magnesium stearate, calcium stearate, potassium oleate, sodium stearate, stearic acid, and sodium palmitate. The therapeutic opioid-nonopioid dual analgesic composition may contain other composition forming ingredients, for example, colorants, compression aids such as microcrystallinecellulose, and binders such as starch. The analgesic composition can be compressed at a 1/8 to 3 ton-force to yield an orally administrable tablet.

Detailed Description Text (64):

A novel and useful therapeutic composition comprising 432 g of a morphine selected from the group consisting of morphine base, morphine pharmaceutically acceptable salt, pharmaceutically acceptable inorganic salt, pharmaceutically acceptable organic salt, morphine hydrobromide, morphine hydrochloride, morphine mucate, morphine N-oxide, morphine sulfate, morphine acetate, morphine phosphate dibasic, morphine phosphate monobasic, morphine inorganic salt, morphine organic salt, morphine acetate trihydrate, morphine bi(heptafluorobutyrate), morphine bi(methylcarbamate), morphine bi(pentafluoropropionate), morphine bi(pyridine-3-carboxylate), morphine bi(trifluoroacetate), morphine bitartrate, morphine chlorhydrate, and morphine sulfate pentahydrate, and 600 g of an analgesic selected from the group consisting of acetaminophen, aspirin, benoxaprofen, flurbiprofen, ibuprofen, indoprofen, propoxyphene, salicylamide, zenazocine and zomepirac are blended with 963 g of poly(alkylene oxide) comprising a 300,000 molecular weight and 90 g of poly(vinyl pyrrolidone) having an average molecular weight of 40,000 are added to a mixing bowl and dry mixed for 12 minutes. Next, 404 g of denatured, anhydrous alcohol is slowly added to the blended composition forming materials with continuous mixing for 15 minutes. Then, the prepared granulation is passed through a 20 mesh screen, and allowed to dry at 25.degree. C. for 18 hrs, and then passed through a 16 mesh screen. The screened granulation is transferred to a planetary mixer, and with constant blending 14.9 g of calcium stearate is added to produce the therapeutic two analgesic composition. The composition is compressed into tablets comprising 350 mg of the therapeutic composition consisting of 70 mg of opioid analgesic and 100 mg of nonopioid analgesic and 180 mg of tablet forming materials. The tablets are compressed under 2.5 tons of pressure to provide a sustained release analgesic tablet.

Detailed Description Text (71):

Next, the bilayer cores, prepared immediately above, were then coated with the laminated membrane of this invention according to the following procedures: First, 154 grams of ethyl cellulose having a molecular weight of approximately 220,000 grams per mole and an ethoxyl content of 48.0 to 49.5 weight percent, 112 grams of hydroxypropyl cellulose having a molecular weight of 80,000 and a molar substitution of 3 and 14

grams of polyoxyethylene (40) stearate was dissolved in 3,720 grams of anhydrous ethanol formula with stirring. The resulting solution was allowed to stand without stirring for 3 days. This solution is referred to as the interior wall forming solution. A second solution was prepared by dissolving 162.5 grams of cellulose acetate having a acetyl content of 39.8 weight percent and an approximate molecular weight of 40,000 grams per mole and 87.5 grams of ethylene oxide-propylene oxide-ethylene oxide triblock copolymer having molecular weight of approximately 8,600 grams per mole and an ethylene oxide content of 82 weight percent in 4,750 grams of anhydrous acetone with stirring and slight warming to 26 degrees centigrade. The resulting solution is the exterior-wall forming solution and it was allowed to stand at ambient room temperature for one day.

Detailed Description Text (87):

When placed in an aqueous environment, water is imbibed by osmosis into the dosage form dissolving the drug and salt to produce an internal osmotic pressure of 287 atmospheres and an ionic strength of 5.47 molar which osmotic pressure and ionic strength is maintained while the drug is dispensed until the last remaining portion of sodium chloride dissolves, at which point in time, the sodium chloride dilutes as a result of the water continuing to flow into the dosage form to lower levels of osmotic pressure and ionic strength, thereby allowing the pore former within the interior wall to dissolve and elute from the wall and thus increase permeability of the wall to compensate for the decrease in osmotic pressure as a result of the dilution. The dosage form meters the release of 8 milligrams of the analgesic at controlled rate over prolonged time.

CLAIMS:

5. A therapeutic solid, sustained-release composition comprising an opioid analgesic and a nonopioid analgesic, wherein the opioid analgesic comprises 0.1 .mu.g to 1000 mg of a member selected from the group consisting of hydromorphone and its pharmaceutically acceptable salts, the nonopioid analgesic comprises 1 mg to 1000 mg of a member selected from the group consisting of aspirin, flurbiprofen, ibuprofen, indoprofen, benoxaprofen, salicylamide, zenazocine and zomepirac, and 10 mg to 500 mg of a pharmaceutically acceptable poly(alkylene oxide) carrier.

10. A therapeutic solid, sustained-release composition comprising a first analgesic selected from the group consisting of morphine and its pharmaceutically acceptable salts, a second analgesic selected from the group consisting of acetaminophen, aspirin, benoxaprofen, flurbiprofen, ibuprofen, indoprofen, salicylamide, zenazocine, and zomepirac, and a pharmaceutically acceptable poly(alkylene oxide) carrier.

WEST

Generate Collection

Print

L2: Entry 42 of 50

File: USPT

Oct 19, 1999

DOCUMENT-IDENTIFIER: US 5968551 A

TITLE: Orally administrable opioid formulations having extended duration of effect

Detailed Description Text (2):

The multiparticulate systems of the present invention may incorporate one or more compounds known as opioid analgesics. Opioid analgesic compounds which may be used in the present invention include alfentanil, allylprodine, alphaprodine, anileridine, benzylmorphine, bezitramide, buprenorphine, butorphanol, clonitazene, codeine, cyclazocine, desomorphine, dextromoramide, dezocine, diampromide, dihydrocodeine, dihydromorphine, dimenoxadol, dimepheptanol, dimethylthiambutene, dioxaphetyl butyrate, dipipanone, eptazocine, ethoheptazine, ethylmethythiambutene, ethylmorphine, etonitazene fentanyl, heroin, hydrocodone, hydromorphone, hydroxypethidine, isomethadone, ketobemidone, levallorphan, levorphanol, levophenacetylmorphan, lofentanil, meperidine, meptazinol, metazocine, methadone, metopon, morphine, myrophine, nalbuphine, narceine, nicomorphine, norlevorphanol, normethadone, nalorphine, normorphine, norpipanone, opium, oxycodone, oxymorphone, papaveretum, pentazocine, phenadoxone, phenomorphan, phenazocine, phenoperidine, piminodine, piritramide, propheptazine, promedol, properidine, propiram, propoxyphene, sufentanil, tramadol, tilidine, salts thereof, mixtures of any of the foregoing, mixed mu-agonists/antagonists, mu-antagonist combinations, and the like.

Detailed Description Text (4):

In one preferred embodiment the sustained-release opioid oral dosage form of the present invention includes hydromorphone as the therapeutically active ingredient in an amount from about 4 to about 64 mg hydromorphone hydrochloride. Alternatively, the dosage form may contain molar equivalent amounts of other hydromorphone salts or of the hydromorphone base. In other preferred embodiments where the opioid analgesic is other than hydromorphone, the dosage form contains an appropriate amount to provide a substantially equivalent therapeutic effect. For example, when the opioid analgesic comprises morphine, the sustained-release oral dosage forms of the present invention include from about 5 mg to about 800 mg morphine, by weight. When the opioid analgesic comprises oxycodone, the sustained-release oral dosage forms of the present invention include from about 5 mg to about 400 mg oxycodone.

Detailed Description Text (7):

The substrates of the present invention may further include one or more additional drugs which may or may not act synergistically with the opioid analgesics of the present invention. Examples of such additional drugs include non-steroidal anti-inflammatory agents, including ibuprofen, diclofenac, naproxen, benoxaprofen, flurbiprofen, fenoprofen, flubufen, ketoprofen, indoprofen, piroprofen, carprofen, oxaprozin, pramoprofen, muprofen, trioxaprofen, suprofen, aminoprofen, tiaprofenic acid, fluprofen, bucloxic acid, indomethacin, sulindac, tolmetin, zomepirac, tiopinac, zidometacin, acemetacin, fentiazac, clidanac, oxpinac, mefenamic acid, meclofenamic acid, flufenamic acid, niflumic acid, tolfenamic acid, diflurisal, flufenisal, piroxicam, sudoxicam or isoxicam, and the like. Other suitable additional drugs which may be included in the dosage forms of the present invention include acetaminophen, aspirin, and other non-opioid analgesics.

Detailed Description Text (16):

In one preferred embodiment, the acrylic coating is an acrylic resin lacquers used in the form of an aqueous dispersion, such as that which is commercially available from Rohm Pharma under the Tradename Eudragit.RTM.. In further preferred embodiments, the acrylic coating comprises a mixture of two acrylic resin lacquers commercially available from Rohm Pharma under the Tradenames Eudragit.RTM. RL 30 D and Eudragit.RTM. RS 30 D, respectively. Eudragit.RTM. RL 30 D and Eudragit.RTM. RS 30 D are copolymers

of acrylic and methacrylic esters with a low content of quaternary ammonium groups, the molar ratio of ammonium groups to the remaining neutral (meth)acrylic esters being 1:20 in Eudragit.RTM. RL 30 D and 1:40 in Eudragit.RTM. RS 30 D. The mean molecular weight is about 150,000. The code designations RL (high permeability) and RS (low permeability) refer to the permeability properties of these agents. Eudragit.RTM. RL/RS mixtures are insoluble in water and in digestive fluids. However, coatings formed from the same are swellable and permeable in aqueous solutions and digestive fluids.

Other Reference Publication (25):

Abraham Sunshine, et al., "Analgesic oral efficacy of tramadol hydrochloride in postoperative pain", Clin. Pharmacol. Ther., Jun. 1992, pp. 740-746.

CLAIMS:

6. The dosage form of claim 1, wherein said opioid analgesic is selected from the group consisting of alfentanil, allylprodine, alphaprodine, anileridine, benzylmorphine, bezitramide, buprenorphine, butorphanol, clonitazene, codeine, cyclazocine, desomorphine, dextromoramide, dezocine, diampromide, dihydrocodeine, dihydromorphine, dimenoxadol, dimepheptanol, dimethylthiambutene, dioxaphetyl butyrate, dipipanone, eptazocine, ethoheptazine, ethylmethylthiambutene, ethylmorphine, etonitazene, fentanyl, heroin, hydrocodone, hydromorphone, hydroxypethidine, isomethadone, ketobemidone, levallorphan, levorphanol, levophenacyl morphan, lofentanil, meperidine, meptazinol, metazocine, methadone, metopon, morphine, myrophine, nalbuphine, narceine, nicomorphine, norlevorphanol, normethadone, nalorphine, normorphine, norpipanone, opium, oxycodone, oxymorphone, papaveretum, pentazocine, phenadoxone, phenomorphan, phenazocine, phenoperidine, piminodine, piritramide, propheptazine, promedol, properidine, propiram, propoxyphene, sufentanil, tramadol, tilidine, salts thereof and mixtures thereof.

39. The dosage form of claim 18, wherein said non-opioid drug is selected from the group consisting of acetaminophen and aspirin.

40. The dosage form of claim 30, wherein said non-opioid drug is selected from the group consisting of acetaminophen and aspirin.

41. The method of claim 13, wherein said non-opioid drug is selected from the group consisting of acetaminophen and aspirin.

42. The method of claim 33, further comprising incorporating a therapeutically effective amount of aspirin or acetaminophen into said unit dose.

45. The method of claim 3, wherein said opioid analgesic is selected from the group consisting of alfentanil, allylprodine, alphaprodine, anileridine, benzylmorphine, bezitramide, buprenorphine, butorphanol, clonitazene, codeine, cyclazocine, desomorphine, dextromoramide, dezocine, diampromide, dihydrocodeine, dihydromorphine, dimenoxadol, dimepheptanol, dimethylthiambutene, dioxaphetyl butyrate, dipipanone, eptazocine, ethoheptazine, ethylmethylthiambutene, ethylmorphine, etonitazene, fentanyl, heroin, hydrocodone, hydromorphone, hydroxypethidine, isomethadone, ketobemidone, levallorphan, levorphanol, levophenacyl morphan, lofentanil, meperidine, meptazinol, metazocine, methadone, metopon, morphine, myrophine, nalbuphine, narceine, nicomorphine, norlevorphanol, normethadone, nalorphine, normorphine, norpipanone, opium, oxycodone, oxymorphone, papaveretum, pentazocine, phenadoxone, phenomorphan, phenazocine, phenoperidine, piminodine, piritramide, propheptazine, promedol, properidine, propiram, propoxyphene, sufentanil, tramadol, tilidine, salts thereof and mixtures thereof.

WEST[Help](#)[Logout](#)[Interrupt](#)[Main Menu](#)[Search Form](#)[Posting Counts](#)[Show S Numbers](#)[Edit S Numbers](#)[Preferences](#)[Cases](#)**Search Results -**

Terms	Documents
tramadol and aspirin	149

Database:

US Patents Full-Text Database
US Pre-Grant Publication Full-Text Database
JPO Abstracts Database
EPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Search:

tramadol and aspirin and molar

[Refine Search](#)[Recall Text](#)[Clear](#)**Search History****DATE:** Thursday, January 09, 2003 [Printable Copy](#) [Create Case](#)Set Name
side by sideQueryHit Count Set Name
result set

DB=USPT,PGPB,JPAB,EPAB,DWPI; PLUR=YES; OP=OR

L1

tramadol and aspirin

149

L1

END OF SEARCH HISTORY

WEST

Generate Collection

Print

6,407,135

L2: Entry 26 of 50

File: USPT

Sep 17, 2002

DOCUMENT-IDENTIFIER: US 6451806 B2

TITLE: Methods and compositions involving opioids and antagonists thereof

Detailed Description Text (28):

In accordance with the present invention, there are provided methods which comprise administering to a patient, inter alia, an opioid compound. A wide variety of opioids are available which may be suitable for use in the present methods and compositions. Generally speaking, it is only necessary that the opioid provide the desired effect (for example, pain alleviation), and be capable of being incorporated into the present combination products and methods (discussed in detail below). In preferred embodiments, the present methods and compositions may involve an opioid which is selected from alfentanil, buprenorphine, butorphanol, codeine, dezocine, dihydrocodeine, fentanyl, hydrocodone, hydromorphone, levorphanol, meperidine (pethidine), methadone, morphine, nalbuphine, oxycodone, oxymorphone, pentazocine, propiram, propoxyphene, sufentanil and/or tramadol. More preferably, the opioid is selected from morphine, codeine, oxycodone, hydrocodone, dihydrocodeine, propoxyphene, fentanyl and/or tramadol.

Detailed Description Text (29):

The opioid component of the present compositions may further include one or more other active ingredients that may be conventionally employed in analgesic and/or cough-cold-antitussive combination products. Such conventional ingredients include, for example, aspirin, acetaminophen, phenylpropanolamine, phenylephrine, chlorpheniramine, caffeine, and/or guaifenesin. Typical or conventional ingredients that may be included in the opioid component are described, for example, in the Physicians' Desk Reference, 1999, the disclosures of which are hereby incorporated herein by reference, in their entirety.

Detailed Description Text (174):

A double-blind Phase II clinical study in 24 young healthy patients undergoing third molar extraction dental surgery showed that the compound of formula (II) (4 mg total oral dose) did not antagonize analgesia or pupil constriction produced by intravenous morphine sulfate. No patients were withdrawn for adverse effects.

CLAIMS:

18. A method according to claim 1 wherein said opioid is selected from the group consisting of alfentanil, buprenorphine, butorphanol, codeine, dezocine, dihydrocodeine, fentanyl, hydrocodone, hydromorphone, levorphanol, meperidine (pethidine), methadone, morphine, nalbuphine, oxycodone, oxymorphone, pentazocine, propiram, propoxyphene, sufentanil and tramadol.

19. A method according to claim 18 wherein said opioid is selected from the group consisting of morphine, codeine, oxycodone, hydrocodone, dihydrocodeine, propoxyphene, fentanyl and tramadol.

40. A method according to claim 25 wherein said opioid is selected from the group consisting of alfentanil, buprenorphine, butorphanol, codeine, dezocine, dihydrocodeine, fentanyl, hydrocodone, hydromorphone, levorphanol, meperidine (pethidine), methadone, morphine, nalbuphine, oxycodone, oxymorphone, pentazocine, propiram, propoxyphene, sufentanil and tramadol.

41. A method according to claim 40 wherein said opioid is selected from the group consisting of morphine, codeine, oxycodone, hydrocodone, dihydrocodeine, propoxyphene, fentanyl and tramadol.

64. A method according to claim 47 wherein said opioid is selected from the group consisting of alfentanil, buprenorphine, butorphanol, codeine, dezocine, dihydrocodeine, fentanyl, hydrocodone, hydromorphone, levorphanol, meperidine (pethidine), methadone, morphine, nalbuphine, oxycodone, oxymorphone, pentazocine, propiram, propoxyphene, sufentanil and tramadol.

65. A method according to claim 64 wherein said opioid is selected from the group consisting of morphine, codeine, oxycodone, hydrocodone, dihydrocodeine, propoxyphene, fentanyl and tramadol.

99. A composition according to claim 83 wherein said opioid is selected from the group consisting of alfentanil, buprenorphine, butorphanol, codeine, dezocine, dihydrocodeine, fentanyl, hydrocodone, hydromorphone, levorphanol, meperidine (pethidine), methadone, morphine, nalbuphine, oxycodone, oxymorphone, pentazocine, propiram, propoxyphene, sufentanil and tramadol.

100. A composition according to claim 99 wherein said opioid is selected from the group consisting of morphine, codeine, oxycodone, hydrocodone, dihydrocodeine, propoxyphene, fentanyl and tramadol.

117. A composition according to claim 102 wherein said opioid is selected from the group consisting of alfentanil, buprenorphine, butorphanol, codeine, dezocine, dihydrocodeine, fentanyl, hydrocodone, hydromorphone, levorphanol, meperidine (pethidine), methadone, morphine, nalbuphine, oxycodone, oxymorphone, pentazocine, propiram, propoxyphene, sufentanil and tramadol.

118. A composition according to claim 117 wherein said opioid is selected from the group consisting of morphine, codeine, oxycodone, hydrocodone, dihydrocodeine, propoxyphene, fentanyl and tramadol.

136. A kit according to claim 120 wherein said opioid is selected from the group consisting of alfentanil, buprenorphine, butorphanol, codeine, dezocine, dihydrocodeine, fentanyl, hydrocodone, hydromorphone, levorphanol, meperidine (pethidine), methadone, morphine, nalbuphine, oxycodone, oxymorphone, pentazocine, propiram, propoxyphene, sufentanil and tramadol.

137. A kit according to claim 136 wherein said opioid is selected from the group consisting of morphine, codeine, oxycodone, hydrocodone, dihydrocodeine, propoxyphene, fentanyl and tramadol.

154. A kit according to claim 139 wherein said opioid is selected from the group consisting of alfentanil, buprenorphine, butorphanol, codeine, dezocine, dihydrocodeine, fentanyl, hydrocodone, hydromorphone, levorphanol, meperidine (pethidine), methadone, morphine, nalbuphine, oxycodone, oxymorphone, pentazocine, propiram, propoxyphene, sufentanil and tramadol.

155. A kit according to claim 154 wherein said opioid is selected from the group consisting of morphine, codeine, oxycodone, hydrocodone, dihydrocodeine, propoxyphene, fentanyl and tramadol.

WEST☐ **Generate Collection** **Print**

L2: Entry 26 of 50

File: USPT

Sep 17, 2002

US-PAT-NO: 6451806

DOCUMENT-IDENTIFIER: US 6451806 B2

TITLE: Methods and compositions involving opioids and antagonists thereof

DATE-ISSUED: September 17, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Farrar; John J.	Chester Springs	PA		

ASSIGNEE-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY	TYPE CODE
Adolor Corporation	Exton	PA			02

APPL-NO: 09/ 725661 [PALM]

DATE FILED: November 29, 2000

PARENT-CASE:

This application was filed as a continuation-in-part of U.S. application Ser. No. 09/450,806, filed Nov. 29, 1999, which was converted to U.S. provisional application Ser. No. 60/304,199.

INT-CL: [07] A61 K 31/44

US-CL-ISSUED: 514/282; 514/295, 514/315, 514/318, 514/316, 514/320, 514/331

US-CL-CURRENT: 514/282; 514/295, 514/315, 514/316, 514/318, 514/320, 514/331

FIELD-OF-SEARCH: 514/315, 514/282, 514/316, 514/318, 514/320, 514/331, 514/295

PRIOR-ART-DISCLOSED:

U.S. PATENT DOCUMENTS

Search Selected**Search ALL**

	PAT-NO	ISSUE-DATE	PATENTEE-NAME	US-CL
<input type="checkbox"/>	<u>3723440</u>	March 1973	Freter et al.	260/293.54
<input type="checkbox"/>	<u>4115400</u>	September 1978	Zimmerman	260/326.5B
<input type="checkbox"/>	<u>4176186</u>	November 1979	Goldbert et al.	424/260
<input type="checkbox"/>	<u>4581456</u>	April 1986	Barnett	546/185
<input type="checkbox"/>	<u>4719215</u>	January 1988	Goldberg	514/282
<input type="checkbox"/>	<u>4730048</u>	March 1988	Portoghese	546/45
<input type="checkbox"/>	<u>4769367</u>	September 1988	Cherry et al.	514/217
<input type="checkbox"/>	<u>4769372</u>	September 1988	Kreek	514/282

<input type="checkbox"/>	<u>4774230</u>	September 1988	Tuttle et al.	514/27
<input type="checkbox"/>	<u>4785000</u>	November 1988	Kreek et al.	514/282
<input type="checkbox"/>	<u>4806556</u>	February 1989	Portoghese	546/44
<input type="checkbox"/>	<u>4861781</u>	August 1989	Goldberg	514/282
<input type="checkbox"/>	<u>4880801</u>	November 1989	Kitchin et al.	514/215
<input type="checkbox"/>	<u>4891379</u>	January 1990	Zimmerman et al.	514/315
<input type="checkbox"/>	<u>4910193</u>	March 1990	Buchheit	514/216
<input type="checkbox"/>	<u>4920102</u>	April 1990	Gidda et al.	514/28
<input type="checkbox"/>	<u>4987136</u>	January 1991	Kreek et al.	514/282
<input type="checkbox"/>	<u>4992450</u>	February 1991	Zimmerman et al.	514/315
<input type="checkbox"/>	<u>5064834</u>	November 1991	Zimmerman et al.	514/279
<input type="checkbox"/>	<u>5102887</u>	April 1992	Goldberg	514/282
<input type="checkbox"/>	<u>5116847</u>	May 1992	Gilbert et al.	514/327
<input type="checkbox"/>	<u>5136040</u>	August 1992	Werner	546/218
<input type="checkbox"/>	<u>5140023</u>	August 1992	Becker et al.	514/214
<input type="checkbox"/>	<u>5159081</u>	October 1992	Cantrell et al.	546/226
<input type="checkbox"/>	<u>5250542</u>	October 1993	Cantrell et al.	514/315
<input type="checkbox"/>	<u>5270328</u>	December 1993	Cantrell et al.	514/331
<input type="checkbox"/>	<u>5280028</u>	January 1994	Flynn et al.	514/294
<input type="checkbox"/>	<u>5319087</u>	June 1994	Zimmerman et al.	546/240
<input type="checkbox"/>	<u>5362756</u>	November 1994	Riviere et al.	514/651
<input type="checkbox"/>	<u>5382591</u>	January 1995	Barberich et al.	514/413
<input type="checkbox"/>	<u>5411745</u>	May 1995	Oshlack et al.	424/456
<input type="checkbox"/>	<u>5422356</u>	June 1995	Zimmerman et al.	514/317
<input type="checkbox"/>	<u>5434171</u>	July 1995	Frank et al.	514/331
<input type="checkbox"/>	<u>5460826</u>	October 1995	Merrill et al.	424/470
<input type="checkbox"/>	<u>5498718</u>	March 1996	Werner	546/348
<input type="checkbox"/>	<u>RE35218</u>	April 1996	Becker et al.	514/214
<input type="checkbox"/>	<u>5520931</u>	May 1996	Persson et al.	424/473
<input type="checkbox"/>	<u>5593695</u>	January 1997	Merrill et al.	424/480
<input type="checkbox"/>	<u>5736550</u>	April 1998	Kikuchi et al.	514/261
<input type="checkbox"/>	<u>5753654</u>	May 1998	Kikuchi et al.	514/230.5
<input type="checkbox"/>	<u>5767083</u>	June 1998	Abajian et al.	514/16
<input type="checkbox"/>	<u>5795861</u>	August 1998	Kolterman et al.	514/12
<input type="checkbox"/>	<u>5811451</u>	September 1998	Minoia et al.	514/443
<input type="checkbox"/>	<u>5849762</u>	December 1998	Farrar et al.	514/327
<input type="checkbox"/>	<u>5855907</u>	January 1999	Payman	424/434
<input type="checkbox"/>	<u>5861014</u>	January 1999	Familoni	607/40

<input type="checkbox"/>	<u>5879705</u>	March 1999	Heafield et al.	424/464
<input type="checkbox"/>	<u>5888529</u>	March 1999	Bunnett et al.	424/422
<input type="checkbox"/>	<u>5968551</u>	October 1999	Oshlack et al.	424/456
<input type="checkbox"/>	<u>5972954</u>	October 1999	Foss et al.	514/282
<input type="checkbox"/>	<u>5972962</u>	October 1999	Belfield et al.	514/315

FOREIGN PATENT DOCUMENTS

FOREIGN-PAT-NO	PUBN-DATE	COUNTRY	US-CL
9176319	November 1992	AU	
506478	September 1992	EP	
1068376	March 1989	JP	
WO 98/25613	June 1998	WO	
WO 99/22737	May 1999	WO	

OTHER PUBLICATIONS

Osol, A. et al. (Eds.), "Analgesics and Antipyretics," Remington's Pharmaceutical Sciences, 15.sup.th Ed., under section entitled Opiate Analgesics, 1975, p. 1098.

Windholz, M., et al. (Eds.), of The Merck Index, An Encyclopedia of Chemicals, Drugs, and Biologicals, 10.sup.th Ed., 1983, No. 2423, p. 350.

"Cancer pain remedy wins orphan drug status," Oncology, 1880, 10(12).

Amin, H.M. et al., "Efficacy of methylnaltrexone versus naloxone for reversal of morphine-induced depression of hypoxic ventilatory response," Anesth. Analog., 1994, 78(4), 701-705 (abstract only).

Amir, S. et al., "Endorphins in endotoxin-induced hyperglycemia in mice," Arch. Toxicol. Suppl., 1983, 6, 261-265 (abstract only).

Argentieri, T.M., et al., "Interaction of the opiate antagonist, naltrexone methyl bromide, with the acetylcholine receptor system of the motor end-plate," Brain Res. (Netherlands), 1983, 277(2), 377-379 (abstract only).

Bado, A., et al., "Endogenous opioid peptides in the control of food intake in cats," Peptides (United States), 1989, 10(5), 967-971 (abstract only).

Bagnol, D., et al., "Cellular Localization and Distribution of the Cloned Mu and Kappa Opioid Receptors in Rat Gastrointestinal Tract," Neuroscience, 1997, 81(2), 579-591.

Bagnol, D., et al., "Changes in enkephalin immunoreactivity of sympathetic ganglia and digestive tract of the cat after splanchnic nerve ligation" Regul. Pept. 1993, 47(3), 259-273.

Bansinath, M., et al., "Evidence for a peripheral action of thyrotropin releasing hormone on gastrointestinal transit in mice," Neuropharmacology, 1988, 27(4), 433-437 (abstract only).

Baratti, C.M., "The impairment of retention induced by pentylene-tetrazol in mice may be mediated by a release of opioid peptides in the brain," Behav. Neural Biol. (United States), 1987, 48(2), 183-196 (abstract only).

Bechara, A., et al., "Peripheral receptors mediate the aversive conditioning effects of morphine in the rat," Pharm. Biochem. Behav. (United States), 1987, 28(2), 219-225 (abstract only).

Bechara, A., et al., "The tegmental pedunculo-pontine nucleus: a brain-stem output of the limbic system critical for the conditioned place preferences produced by morphine and amphetamine," J. Neurosci (United States), 1989, 9(10), 3400-3409 (abstract only).

Bechara A., et al., "Opposite motivational effects of endogenous opioids in brain and periphery," Nature (England), 1985, 314(6011), 533-534 (abstract only).

Berde, C.B., et al., "Peripheral, Spinal, and Supraspinal Targets of Opioids and NSAIDs," IASP Newsletter, 1996, 1-8.

Bergasa, N.V., et al., "Management of the pruritus of cholestasis: potential role of opiate antagonists," Am. J. Gastroenterol, 1991, 86(10), 1404-1412 (abstract only).

Bhargava, H.N. et al., "Effect of nitric oxide synthase inhibition on tolerance to the analgesic action of D-Pen.sup.2, D-Pen.sup.5 enkephalin and morphine in the mouse," Neuropeptides, 1996, 30(3), 219-223.

Bianchetti, A., et al., "Relative affinities of the quaternary narcotic antagonist, N-methyl levallorphan (SR 58002), for different types of opioid receptors" Neuropeptides, 1985, 5(4-6), 379-382 (abstract only).

Bianchetti, A., et al., "Pharmacological actions of levallorphan allyl bromide (CM 32191), a new peripheral narcotic antagonist" *Life Sci*, 31(20-21), 2261-2264 (abstract only).

Bianchi, G., et al., "The peripheral narcotic antagonist N-allyl levallorphan-bromide (CM 32191) selectively prevents morphine antipropulsive action and buprenorphine in-vivo binding in the rat intestine," *J. Pharm. Pharmacol*, 1984, 36(5), 326-330 (abstract only).

Bilsky, E.J., et al., "Effect of Naloxone and D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH.sub.2 and the protein kinase inhibitors H7 and H8 on acute morphine dependence and antinociceptive tolerance in mice," *J. Pharmacol. Exp. Ther.*, 1996, 277, 484-490.

Blank, M.S., et al., "Central, stereoselective receptors mediate the acute effects of opiate antagonists on luteinizing hormone secretion," *Life Sci. (England)*, 1986, 39(17), 1493-1499 (abstract only).

Brown, D.R. et al., "The Use of Quaternary Narcotic Antagonists in Opiate Research," *Neuropharmacology*, 1985, 24(3), 181-191.

Brown, D.R., et al., "Reversal of Morphine-Induced Catalepsy in the Rat by Narcotic Antagonists and Their Quaternary Derivatives," *Neuropharmacology*, 1983, 22(3A), 317-321.

Brown, D.R., et al., "Opiate antagonists: central sites of action in suppressing water intake of the rat," *Brain Res.*, 1981, 221(2), 432-436 (abstract only).

Calcagnetti, D.J., et al., "Central and peripheral injection of quaternary antagonist, SR58002C, reduces drinking" *Physiol. Behav.*, 1987, 40(5), 573-575 (abstract only).

Calcagnetti, D.J., et al., "Quaternary naltrexone reveals the central mediation of conditional opioid analgesia," *Pharma. Biochem. Behav. (United States)*, 1987, 27(3), 529-531 (abstract only).

Caldwell, R.W., et al., "Actions of the opioid antagonist, nalmefene, and congeners on reperfusion cardiac arrhythmias and regional left coronary blood flow," *Pharmacology*, 1990, 41(3), 161-166 (abstract only).

Carr, K.D., et al., "Effects of naloxone and its quaternary analogue on stimulation-induced feeding," *Neuropharmacology (England)*, 1983, 22(1), 127-130 (abstract only).

Corrigall, W.A., et al., "An analysis of the paradoxical effect of morphine on runway speed and food consumption," *Psychopharmacology*, 1986, 89(3), 327-333 (abstract only).

Corrigall, W.A., "Heroin self-administration: effects of antagonist treatment in lateral hypothalamus," *Pharmacol. Biochem. Behav.*, 1987, 27(4), 693-700 (abstract only).

Corrigall, W.A., et al., "Antagonist treatment in nucleus accumbens or periaqueductal grey affects heroin self-administration," *Pharmacol. Biochem. Behav.*, 1988, 30(2), 443-450 (abstract only).

Culpepper-Morgan, J.A., et al., "Treatment of opioid-induced constipation with oral naloxone: A pilot study," *Clin. Pharmacol. Ther.*, 1992, 90-95.

De Winter, Benedicte, et al., "Differential effect of indomethacin and ketorolac on postoperative ileus in rats," *Eur. J. Pharmacol*, 1998, 344, 71-76.

Dickson, P.R., et al., "GRF-induced feeding: evidence for protein selectivity and opiate involvement," *Peptides*, 1994, 15(8), 1343-1352 (abstract only).

Dorland's Illustrated Medical Dictionary, 24.sup.th ed., W.B. Saunders Company, Philadelphia 1965, 724.

Dorland's Illustrated Medical Dictionary, 27th ed., W.B. Saunders Company, Philadelphia 1998, 816.

Dorland's Illustrated Medical Dictionary, 27th ed., W.B. Saunders Company, Philadelphia 1988, 375.

Dourish, C.T., et al., "Enhancement of morphine analgesia and prevention of morphine tolerance in the rat by the cholecystokinin antagonist L-364, 718," *Eur. J. Pharmacol*, 1988, 147, 469-472.

Dragnonetti, M., et al., "Levallorphan methyl iodide (SR 58002), a potent narcotic antagonist with peripheral selectivity superior to that of other quaternary compounds", *Life Sci.*, 1973, 33, Suppl. 1, 477-480 (abstract only).

Ellis, J.E., et al., "Premedication with oral and transdermal clonidine provides safe and efficacious postoperative sympathectomy," *Anesth. Analg.*, 1994, 79(6), 1133-1140 (abstract only).

Ferraz, Alvaro, A.B., M.D., et al., "Nonopioid Analgesics Shorten the Duration of Postoperative Ileus," *Dept. of Surgery and Physiology and Surgical Research Service*, 1995, vol. 61, 1079-1083.

Fletcher, P.J., "Opiate antagonists inhibit feeding induced by 8-OH-DPAT: possible mediation in the nucleus accumbens," *Brain Res.*, 1991, 560(1-2), 260-267 (abstract only).

Foss, J.F., et al., "Peripheral Antagonism of the Emetic Effect of Morphine by Methylnaltrexone," *Clinical Res.*, 1989, 37(2), 595A (abstract only).

Foss, J.F., et al., "Dose-Related Antagonism of the Emetic Effect of Morphine by Methylnaltrexone in Dogs," *J. Clin. Pharmacol.*, 1993, 33, 747-751.

Foss, J.F., "Excretion of Methylnaltrexone After a Single Oral Dose of the Compound," National Center for Research Resources, 1999, 1 page (summary only).

Foss, J.F., et al., "Safety and tolerance of methylnaltrexone in healthy humans: a randomized, placebo-controlled, intravenous, ascending-dose, pharmacokinetic study," *J. Clin. Pharmacol.*, 1997, 37(1), 25-30 (abstract only).

Foss, J.F., et al., "Effects of methylnaltrexone on morphine-induced cough suppression in guinea pigs," *Life Sci.*, 1996, 59(15), 235-238 (abstract only).

Fotherby, F.J., et al., "Idiopathic slow-transit constipation: whole gut transit times, measured by a new simplified method, are not shortened by opioid antagonists," *Aliment Pharmacol Ther.*, 1987, 1(4), 331-338.

Fox, D.A., et al., "Roles of central and peripheral mu, delta, and kappa opioid receptors in the mediation of gastric acid and secretory effects in the rat," *Dept. Pharma.*, 1988, 244(2), 456-462 (abstract only).

France, C.P., et al., "Comparison of naltrexone and quaternary naltrexone after systemic and intracerebroventricular administration in pigeons," *Neuropharmacology (England)*, 1987, 26(6), 541-548 (abstract only).

Friese, N., et al., "Reversal by K-Agonists of Peritoneal Irritation-Induced Ileus and Visceral Pain in Rats," *Life Sciences*, 1997, vol. 60(9), 625-634.

Greene, T.W., et al., *Protective Groups in Organic Synthesis 2.sup.nd Ed.*, Wiley & Sons, 1991.

Hocking, M.P., "The effect of opioid receptor antagonist on postoperative ileus," *Dept. Vet. Affairs*, 1996 (abstract only).

Howd, R.A., et al., "Naloxone and Intestinal Motility," *SR International, Life Sciences Division*, 1978, 34(10), 1310-1311.

Introini, I.B., et al., "Pharmacological evidence of a central effect of naltrexone, morphine, and beta-endorphin and a peripheral effect of met- and leu-enkephalin on retention of an inhibitory response in mice," *Behav. Neural. Biol. (United States)*, 1985, 44(3), 434-436 (abstract only).

Jalowiec, J.E., "Suppression of juvenile social behavior requires antagonism of central opioid systems," *Pharmacol Biochem Behav. (United States)*, 1989, 33(3), 697-700 (abstract only).

Kalivas, P.W., et al., "Enkephalin release into the ventral tegmental area in response to stress: modulation of mesocorticolimbic dopamine," *Brain Res. (Netherlands)*, 1987, 414(2), 339-348 (abstract only).

Kam, P.C., et al., "Pruritis--itching for a cause and relief?" *Anaesthesia*, 1996, 51(12), 1133-1138 (abstract only).

Kapusta, D.R., et al., "Opioids in the systemic hemodynamic and renal responses to stress in spontaneously hypertensive rats," *Hypertension (United States)*, 1989, 13(6 Pt. 2), 808-816 (abstract only).

Kastin, A.J., et al., "EEG evidence that morphine and an enkephalin analog cross the blood-drain barrier," *Pharmacol. Biochem. Behav.*, 1991, 40(4), 771-774 (abstract only).

Kelley, Mark C., et al., "Ketorolac Prevents Postoperative Small Intestinal Ileus in Rats," *American Journal of Surgery*, 1993, vol. 165, 107-112.

Kelly, S.J., et al., "Role of peripheral and central opioid activity in analgesia induced by restraint stress," *Life Sci. (England)*, 1987, 41(6), 789-794 (abstract).

Koch, T.R., et al., "Inhibitory neuropeptides and intrinsic inhibitory innervation of descending human colon," *Digest. Dis. Sci.*, 1991, 36(6), 712-728 (abstract only).

Koob, G.F., et al., "Effects of opiate antagonists and their quaternary derivatives on heroin self-administration in the rat," *J. Pharmacol Exp. Ther. (United States)*, 1984, 229(2), 481-486 (abstract only).

Kotake, A.M., et al., "Variations in Demethylation of N-methylnaltrexone in Mice, rats, dogs, and humans," *Xenobiotica*, 1989, 19(11), 1247-1254 (abstract only).

Kreek, M.J., et al., "Naloxone, A Specific Opioid Antagonist, Reverses Chronic Idiopathic Constipation," *Lancet*, 1983, 1(8319), 261-262.

Kuhn, F.J., et al., "Study on novel morphine antagonists in the animal experiment," *Arzneimittelforschung*, 1976, 26(11), 2009-2014 (abstract only).

Kuhn, F.J., et al., "Prufung Einiger Neuer Morphinantagonisten im Tierexperiment," *Arzneimittel Forschung Drug Research*, 1976, 26, 2009-2014.

Latasch, L., et al., "Aufhebung einer Morphin-induzierten Obstipation durch orales Naloxon," *Anaesthesist*, 1997, 46, 191-194 (not in English).

Linseman, M.A., "Central vs. peripheral mediation of opioid effects on alcohol consumption in free-feeding rats," *Pharmacol Biochem. Behav. (United States)*, 1989, 33(2), 407-413 (abstract only).

Linseman, M.A., et al., "Effects of opioids on the absorption of alcohol," *Pharmacol Biochem. Behav. (United States)*, 1997, 58(1), 79-84 (abstract only).

Livingston, E.H., et al., "Postoperative Ileus," *Dig. Dis. Sci.*, 1990, 35(1), 121-132.

Locke, K.W., et al., "Characterization of the discriminative stimulus effects of centrally administered morphine in the rat," *Psychopharmacology (Berl.)* (W. Germany), 1985, 87(1), 1-6 (abstract only).

Loew, G.H., "Molecular: The designer's goal is to eliminate adverse side effects," *Modern Drug. Disc.*, 1999, 24-30.

Macfadyen, A.J., et al., "Pain management in the pediatric intensive care unit," *Critical Care Clinics, Pain Management*, 1999, 15(1), 185-200.

Mack, D.J., et al., "Paralytic ileus: response to naloxone," *Br. J. Surg.*, 1989, 76(10), 1101.

Mao, M.J., et al., "Oral administration of dextromethorphan prevents the development of morphine tolerance and dependence in rats," *Pain*, 1996, 67, 361-368.

Marks-Kaufman, R., et al., "Central and peripheral contributions of endogenous opioid systems to nutrient selection in rats," *Psychopharmacology (Berl.)* (W. Germany), 1985, 85(4), 414-418 (abstract only).

Martin, G.M., et al., "Morphine preexposure attenuates the aversive properties of opiates without preexposure to the aversive properties," *Pharmacol Biochem. Behav.* (United States), 1988, 30(3), 687-692 (abstract only).

McArdle, P., et al., "Intravenous analgesia," *Critical Care Clinics, Pain Management*, 1999, 15(1), 89-104.

Mickley, G.A., et al., "Quaternary naltrexone reverses morphine-induced behaviors," *Physiol Behav.* (United States), 1985, 35(2), 249-253 (abstract only).

Misra A.L., et al., "Intravenous kinetics and metabolism of [15, 16-3H] naltrexonium methiodide in the rat," *J. Pharm. Pharmacol* (England), 1987, 39(3), 225-227 (abstract only).

Moerman, I., et al., "Evaluation of methylnaltrexone for the reduction of postoperative vomiting and nausea incidences," *Acta Anaesth.*, 1995, 46, 127-132.

Mucha, R.F., "Is the motivational effect of opiate withdrawal reflected by common somatic indices of precipitated withdrawal? A place conditioning study in the rat," *Brain Res.* (Netherlands), 1987, 418(2), 214-220 (abstract only).

Mucha, R.F., "Taste aversion involving central opioid antagonism is potentiated in morphine-dependent rats," *Life Sci.* (England), 1989, 45(8), 671-678 (abstract only).

Murphy, D.B., et al., "Opioid-induced delay in gastric emptying: a peripheral mechanism in humans," *Anesthesiology*, 1997, 87(4), 765-770 (abstract only).

Naranjo, J.R., et al., "Evidence for a central but not adrenal, opioid mediation in hypertension induced by brief isolation in the rat," *Life Sci.* (England), 1986, 38(21), 1923-1930 (abstract only).

Nichols, M.L. et al., "Enhancement of the antiallodynic and antinociceptive efficacy of spinal morphine by antisera to dynorphin A (1-13) or MK-801 in a nerve-ligation model of peripheral neuropathy," *Pain*, 1997, 69, 317-322.

Orchin, et al., *The Vocabulary of Organic Chemistry*, John Wiley and Sons Inc., 1980, 126.

Physicians' Desk Reference, 1999.

Quock R.M., et al., "Narcotic antagonist-induced hypotension in the spontaneously hypertensive rat," *Life Sci.* (England), 1985, 37(9), 819-826 (abstract only).

Quock, R.M., et al., "Central pharmacological activity of a quaternary ammonium compound in streptozotocin diabetic mice," *Life Sci.* (England), 1988, 43(17), 1411-1417 (abstract only).

Quock, R.M., et al., "Influence of narcotic antagonist drugs upon nitrous oxide analgesia in mice," *Brain Res.* (Netherlands), 1988, 440(1), 35-41 (abstract only).

Rae, G.A., et al., "Methylnalorphinium fails to reverse naloxone-sensitive stress-induced analgesia in mice," *Pharmacol Biochem Behav.*, 1986, 24(4), 829-832 (abstract only).

Ramarao, P., "Evidence for the involvement of central opioidergic systems in L-tyrosine methyl ester-induced analgesia in the rat," *Pharmacology (Switzerland)*, 1988, 37 (1), 1-7 (abstract only).

Ramabadran, K., "Effects of N-Methylnaloxane and N-Methylnaltrexone on Nociception and Precipitated Abstinence in Mice," *Life Sci.*, 1982, 31(12-13), 1253-1256.

Reisine, T., et al., "Opioid analgesics and antagonists," Hardman, J.G. et al., eds. *And Goodman & Gilman's The Pharmacological Basis of Therapeutics Ninth Edition* 1996, 521-555.

Remington's Pharmaceutical Sciences, Mack Pub. Co., Easton, PA, 1980.

Resnick J., "Delayed Gastric Emptying and Postoperative Ileus after Nongastric Abdominal Surgery: Part II," *Am. J. Gastroenterology*, 1997, 92(6), 934-940.

Resnick, J., "Delayed Gastric Emptying and Postoperative Ileus after Nongastric Abdominal Surgery: Part I," *Am. J. Gastroenterology*, 1997, 92(5), 751-762.

Riviere, Pierre J.M., et al., "Fedotozine Reverses Ileus Induced by Surgery or Peritonitis: Action at Peripheral κ -Opioid Receptors," *Gastroenterology*, 1993, 104, 724-731.

Roger, T., "Colonic motor responses in the pony: relevance of colonic stimulation by

opiate antagonists," *Am. J. Vet Res.*, 1985, 46(1), 31-35, (abstract only).
Rosnow, C.E., "Methylnaltrexone: reversing the gastrointestinal effects of opioids," *Anesthesiology*, 1997, 87(4), 736-737.
Russell, James, et al., "Antagonism of Gut, but Not Central Effects of Morphine with Quaternary Narcotic Antagonists," *Eur. J. Pharmacol*, 1982, 78, 255-261 (abstract only).
Sbacchi M., et al., "Antagonism by N-methyl levallorphan-methane sulphonate (SR 58002 C) of morphine-elicited acute and chronic central and peripheral effects," *Life Sci.*, 1988, 42(21), 2079-2089 (abstract only).
Schang, J.C., et al., "Beneficial Effects of Naloxone in a Patient with Intestinal Pseudoobstruction," *Am. J. Gastroenterol.*, 1985, 80(6), 407-411.
Schmidhammer et al., "30. Synthesis and Riological Evaluation of 14-Alkoxymorphinans"; "14-O-Ethyl-5-methylnaltrexone, an Opioid Antagonist with Unusual Selectrivity," *Helvetica Chimica Acta*, 1993, (76), 476-480.
Schuller, A.G.P., et al., "But Not Morphine, Inhibits GI Transit in Mu Opioid Receptor Deficient Mice," *Soc. Neurosci. Abstr.*, 1998, 24, 524.
Shaham, Y., et al., "Effects of restraint stress and intra-ventral tegmental area injections of morphine and methyl naltrexone on the discriminative stimulus effects of heroin in the rat," *Pharmacol Biochem. Behav.* (United States), 1995, 51(2-3), 491-498 (abstract only).
Solvason, H.B., et al., "Naltrexone blocks the expression of the conditioned elevation of natural killer cell activity in BALB/c mice," *Brain Behav. Immun.* (United States), 1989, 3(3), 247-262 (abstract only).
Sykes, N.P., "An investigation of the ability of oral naloxone to correct opioid-related constipation in patients with advanced cancer," *Palliative Medicine*, 1996, 10, 135-144.
Taber's Cyclopedic Medical Dictionary, F.A. Davis Company, Philadelphia, 15 ed., 1985, 824-825.
Tavani, A., et al., "Morphine no longer blocks gastrointestinal transit but retains antinociceptive action in diallylnormorphine-pretreated rats," *Eur. J. Pharmacol*, 1979, 59(1-2), 151-154 (abstract only).
Trujillo, K.A., et al., "Effects of opiate antagonists and their quaternary analogues on nucleus accumbens self-stimulation," *Behav. Brain Res.* (Netherlands), 1989, 181-188 (abstract only).
Vaccarino, F.J., et al., "Effects of opiate antagonist treatment into either the periaqueductal grey or nucleus accumbens on heroin-induced locomotor activation," *Brain Res. Bull.* (United States), 1987, 19 (5), 545-549 (abstract only).
Valentino, Rita J., et al., "Quaternary Naltrexone: Evidence for the Central Mediation of Discriminative Stimulus Effects of Narcotic Agonists and Antagonists," *CNS mediation of narcotic discrimination*, 1981, vol. 217(3), 652-659.
Valentino, Rita J., et al., "Receptor Binding, Antagonist, and Withdrawal Precipitating Properties of Opiate Antagonists," *Life Sciences*, 1983, vol. 32, 2887-2896.
van der Kooy, D., et al., "Hyperalgesia mediated by peripheral opiate receptors in the rat," *Behav. Brain Res*, 1985, 17(3), 203-211 (abstract only).
Vollmar A.M., et al., "The effect of opioids on rat plasma atrial natriuretic peptide," *Eur. J. Pharmacol* (Netherlands), 1987, 143(3), 315-321 (abstract only).
Wittert, G., et al., "Tissue Distribution of Opioid Receptor Gene Expression in the Rat," *Biochem. Biophys. Res. Commun.*, 1996, 218, 877-881.
Yuan, C.S., et al., "Efficacy of orally administered methylnaltrexone in decreasing effects after intravenous morphine," *Drug. Alcohol Dependence*, 1998, 52, 161-165.
Yuan, C.S., et al., "Methylnaltrexone for Reversal of Constipation Due to Chronic Methadone Use," *JAMA*, 2000, 283(3), 13 pages.
Yuan, C.S., et al., "Effects of intravenous methylnaltrexone on opioid-induced gut motility and transit time changes in subjects receiving chronic methadone therapy: a pilot study," *Pain*, 1999, 82, 1-15.
Yuan, C.S., et al., "Effects of methylnaltrexone on morphine-induced inhibition of contraction in isolated guinea-pig ileum and human intesting," *Eur. J. Pharmacol.*, 1995, 276(1-2), 107-111 (abstract included only).
Yuan, C.S., et al., "Methylnaltrexone Prevents Morphine-Induced Delay in Oral-Cecal Transit Time Without Affecting Analgesia: A Double-Blind Randomized Placebo-Controlled Trial," *Clin Pharmacol Ther.* (United States), 1996, 59(4), 469-475 (abstract only).
Yuan, C.S., et al., "The safety and efficacy of oral methylnaltrexone in preventing morphine-induced delay in oral-cecal transit time," *Clin Pharmacol Ther.* (United States), 1997, 61(4), 467-475 (abstract only).
Zimmerman, D.M., et al., "Discovery of a Potent, Peripherally Selective trans-3,4-Dimethyl-4-(3-hydroxyphenyl) piperidine Opioid Antagonist for the Treatment of Gastrointestinal Motility Disorders," *J. Med. Chem.*, 1994, 37, 2262-2265.
Zimmerman, D.M., et al., "LY246736 Dihydrate," *Drugs Future*, 1994, 19(12), 1078-1083.

ART-UNIT: 1614

PRIMARY-EXAMINER: Reamer; James H.

ABSTRACT:

Novel methods and compositions comprising opioids and opioid antagonists. In preferred embodiments, the methods and compositions comprise opioids and peripheral mu opioid antagonist compounds. The methods and compositions are particularly suitable for treating and/or preventing side effects associated with opioids including, for example, constipation, vomiting and/or nausea.

164 Claims, 3 Drawing figures